Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCCNASDAQ:KALVNASDAQ:TOCANASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$2.00-9.1%$4.06$1.95▼$49.34$28.51M0.52104,885 shs144,475 shsKALVKalVista Pharmaceuticals$11.93+2.3%$12.02$7.30▼$15.50$593.11M0.05420,599 shs413,615 shsTOCATocagen$7.85+0.3%$32.24$0.42▼$6.77$187.76M0.011.47 million shs21,295 shsXNCRXencor$8.06-1.7%$10.18$7.16▼$27.24$573.49M0.99646,222 shs728,455 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals0.00%+687.09%-44.71%-66.37%-94.88%KALVKalVista Pharmaceuticals0.00%+0.25%-0.58%+22.23%-0.67%TOCATocagen+0.26%+23.04%+8.13%-34.58%+1,126.56%XNCRXencor0.00%-3.24%-16.91%-50.58%-62.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCCCyclacel Pharmaceuticals0.6468 of 5 stars0.02.00.00.02.92.50.0KALVKalVista Pharmaceuticals4.3844 of 5 stars3.63.00.04.43.02.50.6TOCATocagenN/AN/AN/AN/AN/AN/AN/AN/AXNCRXencor3.4214 of 5 stars3.40.00.03.91.80.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AKALVKalVista Pharmaceuticals 3.13Buy$24.83108.16% UpsideTOCATocagen 0.00N/AN/AN/AXNCRXencor 2.89Moderate Buy$29.50266.00% UpsideCurrent Analyst Ratings BreakdownLatest TOCA, KALV, XNCR, and CYCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.004/30/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.004/21/2025XNCRXencorWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/8/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/26/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/26/2025KALVKalVista PharmaceuticalsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/14/2025KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/13/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.002/28/2025XNCRXencorWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $33.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$43K602.74N/AN/A$0.57 per share3.51KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.86 per shareN/ATOCATocagen$40K4,694.10N/AN/A$0.45 per share17.44XNCRXencor$127.23M4.51N/AN/A$10.99 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$22.56M-$56.00N/A∞N/A-18,150.00%-1,901.11%-188.23%N/AKALVKalVista Pharmaceuticals-$126.64M-$3.72N/AN/AN/AN/A-103.92%-88.06%7/10/2025 (Estimated)TOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/AXNCRXencor-$126.09M-$3.06N/AN/AN/A-232.77%-30.92%-21.74%8/4/2025 (Estimated)Latest TOCA, KALV, XNCR, and CYCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025XNCRXencor-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$4.64-$5.28-$0.64-$0.33$0.01 million$0.01 million2/27/2025Q4 2024XNCRXencor-$0.81-$0.62+$0.19-$0.62$17.14 million$52.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel Pharmaceuticals$0.157.50%N/AN/A N/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ALatest TOCA, KALV, XNCR, and CYCC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$2.404/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A0.770.77KALVKalVista PharmaceuticalsN/A6.876.87TOCATocagen1.881.151.15XNCRXencor0.016.236.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%KALVKalVista PharmaceuticalsN/ATOCATocagen21.42%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals68.00%KALVKalVista Pharmaceuticals10.50%TOCATocagen10.90%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals1412.96 million4.78 millionOptionableKALVKalVista Pharmaceuticals10049.72 million44.23 millionOptionableTOCATocagen7723.92 millionN/ANot OptionableXNCRXencor28071.15 million66.32 millionOptionableTOCA, KALV, XNCR, and CYCC HeadlinesRecent News About These CompaniesNorthern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR)May 17 at 3:44 AM | marketbeat.comBrokerages Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $29.50May 17 at 3:27 AM | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 16 at 2:58 AM | marketbeat.comJacobs Levy Equity Management Inc. Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)May 15 at 5:41 AM | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)May 13, 2025 | theglobeandmail.comLeerink Partnrs Has Bearish Forecast for Xencor Q2 EarningsMay 13, 2025 | marketbeat.comWedbush Comments on Xencor's Q2 Earnings (NASDAQ:XNCR)May 13, 2025 | marketbeat.comResearch Analysts Set Expectations for Xencor Q2 EarningsMay 13, 2025 | marketbeat.comLeerink Partnrs Estimates Xencor's Q2 Earnings (NASDAQ:XNCR)May 13, 2025 | americanbankingnews.comWedbush Weighs in on Xencor's Q2 Earnings (NASDAQ:XNCR)May 13, 2025 | americanbankingnews.comEquities Analysts Offer Predictions for Xencor Q2 EarningsMay 13, 2025 | americanbankingnews.comWhat is William Blair's Forecast for Xencor Q4 Earnings?May 11, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Price Target Lowered to $6.00 at BarclaysMay 10, 2025 | americanbankingnews.comDeep Track Capital LP Has $11.49 Million Stake in Xencor, Inc. (NASDAQ:XNCR)May 9, 2025 | marketbeat.comBraidwell LP Buys 149,083 Shares of Xencor, Inc. (NASDAQ:XNCR)May 8, 2025 | marketbeat.comXencor Reports First Quarter 2025 Financial ResultsMay 7, 2025 | uk.finance.yahoo.comXencor (XNCR) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comXencor (NASDAQ:XNCR) Trading Down 6.1% - Should You Sell?May 7, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 SharesMay 7, 2025 | insidertrades.comDimensional Fund Advisors LP Grows Position in Xencor, Inc. (NASDAQ:XNCR)May 7, 2025 | marketbeat.comBVF Inc. IL Acquires 1,438,760 Shares of Xencor, Inc. (NASDAQ:XNCR)May 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOCA, KALV, XNCR, and CYCC Company DescriptionsCyclacel Pharmaceuticals NASDAQ:CYCC$2.00 -0.20 (-9.09%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$2.04 +0.04 (+2.25%) As of 05/16/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.KalVista Pharmaceuticals NASDAQ:KALV$11.93 +0.27 (+2.32%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$11.93 0.00 (0.00%) As of 05/16/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Tocagen NASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.Xencor NASDAQ:XNCR$8.06 -0.14 (-1.71%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$8.06 0.00 (0.00%) As of 05/16/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
